A Phase II Study of Crenolanib Besylate in Subjects With Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

Trial Profile

A Phase II Study of Crenolanib Besylate in Subjects With Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Crenolanib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors AROG Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 May 2016 Data will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, according to an Arog Pharmaceuticals media release.
    • 09 Dec 2015 Pharmacokinetic and retrospective analysis data from this and another phase II trial (ARO005) presented at the 57th American Society of Hematology (ASH) Annual Meeting, according to an AROG Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top